These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32166937)

  • 1. Surveillance for hepatocellular carcinoma after hepatitis C virus eradication.
    Testino G
    Minerva Med; 2022 Jun; 113(3):569-570. PubMed ID: 32166937
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
    Zhu F; Li X
    J Formos Med Assoc; 2021 Apr; 120(4):1160. PubMed ID: 33293200
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma".
    Cheng YM; Tzeng IS; Kao JH; Wang CC
    J Formos Med Assoc; 2021 Apr; 120(4):1161-1164. PubMed ID: 33358562
    [No Abstract]   [Full Text] [Related]  

  • 4. [Residual risk of liver disease after hepatitis C virus eradication].
    Ongaro M; Mathys P; Zampaglione L; Negro F
    Rev Med Suisse; 2021 Sep; 17(748):1453-1456. PubMed ID: 34468096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'.
    Semmler G; Mandorfer M
    J Hepatol; 2022 Aug; 77(2):571-572. PubMed ID: 35526785
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
    J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    Seko Y; Moriguchi M; Takahashi A; Yamaguchi K; Umemura A; Okuda K; Kataoka S; Unozawa H; Kobayashi K; Ogasawara S; Sato R; Tsuchiya S; Watanabe S; Morimoto N; Iwai K; Aramaki T; Kato N; Itoh Y
    J Gastroenterol; 2022 Feb; 57(2):90-98. PubMed ID: 35031857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    Nabatchikova E; Abdurakhmanov D; Rozina T; Nikulkina E; Tanaschuk E; Moiseev S
    J Hepatol; 2020 Aug; 73(2):469-470. PubMed ID: 32498974
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases.
    Tapia-Sosa R; Hernández-Cabral F; Gabutti A; Páez-Zayas VM; García-Juárez I
    Rev Gastroenterol Mex (Engl Ed); 2021; 86(2):197-199. PubMed ID: 33187768
    [No Abstract]   [Full Text] [Related]  

  • 10. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?
    Isfordink CJ; Maan R; de Man RA; van Erpecum KJ; van der Meer AJ
    Eur J Intern Med; 2021 Dec; 94():6-14. PubMed ID: 34563447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakthroughs in hepatitis C research: from discovery to cure.
    Manns MP; Maasoumy B
    Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):533-550. PubMed ID: 35595834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patients with HCV advanced chronic liver disease after oral antivirals".
    Genescà J
    J Hepatol; 2020 Aug; 73(2):472-473. PubMed ID: 32493575
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hepatitis C virus infection and hepatocarcinogenesis].
    Berta E; Egresi A; Bacsárdi A; Gáspár Z; Lengyel G; Hagymási K
    Orv Hetil; 2019 Jun; 160(22):846-853. PubMed ID: 31131608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C.
    Miyano S; Togashi H; Shinzawa H; Sugahara K; Matsuo T; Takeda Y; Saito K; Saito T; Ishiyama S; Kaneko M; Takahashi T
    J Gastroenterol Hepatol; 1999 Sep; 14(9):928-30. PubMed ID: 10535477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
    Kurokawa K; Ohki T; Kato J; Fukumura Y; Imai M; Shibata C; Arai J; Kondo M; Takagi K; Kojima K; Seki M; Mori M; Toda N; Tagawa K
    J Med Case Rep; 2020 May; 14(1):62. PubMed ID: 32456712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
    J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].
    Hamdane N; Baumert TF; Zeisel MB
    Med Sci (Paris); 2018 May; 34(5):391-394. PubMed ID: 29900836
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
    Muzica CM; Stanciu C; Huiban L; Singeap AM; Sfarti C; Zenovia S; Cojocariu C; Trifan A
    World J Gastroenterol; 2020 Nov; 26(43):6770-6781. PubMed ID: 33268960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Hernaez R; Thimme R
    Gut; 2022 Mar; 71(3):454-456. PubMed ID: 33785552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.